Conclusion imho: The company prepared a presentation that showed that high doses had the best chance of succeeding and then they used the low doses instead.
They started referring to “concentration” instead of dose, they appear to have put some effort into hiding the doses in the 2b/3 trial from investors.
Imho someone should put the CEO on the spot and demand an explanation.
News 
Market Data 
Discover 
